hippocampus, alone and augments the effect of atypical antipsychotic
drugs"
Poster Session 874
Wednesday, November 19, 2008
1:00 p.m. - 5:00 p.m. EST
-- "Serotonin 5-HT(6) receptor antagonists modulate episodic, spatial
and working memory, highlighting a potential therapeutic role in
alleviating deficits associated with mild cognitive impairment and
Alzheimer's disease"
Poster Session 685
Tuesday, November 18, 2008
1:00 p.m. - 5:00 p.m. EST
-- "Identification and characterization of a novel small molecule
inhibitor for phosphodiesterase 10A as a potential PET-tracer using
LC-MS/MS"
Poster Session 885
Wednesday, November 19, 2008
1:00 p.m. - 5:00 p.m. EST
-- "Camk2(alpha) Heterozygous knock-out mice: a model of bipolar
disorder-related mania"
Poster Session 157
Sunday, November 16, 2008
8:00 a.m. - 12:00 p.m. EST
-- "Age and task dependent alterations in cognitive performance exist
in the rTg4510 mouse model of human tauopathy"
Poster Session 439
Monday, November 17, 2008
1:00 p.m. - 5:00 p.m. EST
-- "Behavioral characterization of rTg4510 tau transgenic mice"
Poster Session 439
Monday, November 17, 2008
1:00 p.m. - 5:00 p.m. EST
About the Company
Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.
Safe Harbor Statement
This press
'/>"/>
| SOURCE Memory Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved |